Financial services companies have unique needs when it comes to business AI. They operate in one of the most highly regulated sectors while responding to external events that are updated by the second. As a result, the success of agentic AI in financial services depends less on the sophistication of the system and more on […]
AI Drives Cybersecurity Investments, Widening ‘Valley of Death’
In a role reversal, investment dollars in AI security startups exceeded the value of AI acquisitions in 1Q26 by more than $1 billion, a rare occurrence.
Regenxbio’s Duchenne gene therapy clears phase 3 hurdle
Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche’s Elevidys.
Foxconn Attack Highlights Manufacturing’s Cyber Crisis
A Nitrogen ransomware attack on Foxconn’s North American facilities is one of 600 hits on manufacturers this year, as gangs increasingly target the sector for its low tolerance for downtime.
Eli Lilly delivers $50M boost to UNICEF’s pediatric health push
Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to improve the prevention, detection and management of noncommunicable diseases.
Biogen’s anti-tau Alzheimer’s drug misses Phase 2 goal, but claims signs of efficacy
Here we go again? Biogen reported heavily anticipated Alzheimer’s data on Thursday morning, saying its tau-targeting drug BIIB080 did not meet its primary endpoint in a Phase 2 study. But the company said it slowed …
FDA hands BeOne, Taiho approvals for blood cancers
BeOne’s gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho’s Inqovi has acute myeloid leukaemia added to its label.
Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approval
Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA approval in 2027. The biotech hopes to be the second company to commercialize …
BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label. The FDA greenlit …
AZ cues up broader use of Imfinzi in bladder cancer
The results of the VOLGA trial have buoyed AstraZeneca’s ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.
The shock of seeing your body used in deepfake porn
When Jennifer got a job doing research for a nonprofit in 2023, she ran her new professional headshot through a facial recognition program. She wanted to see if the tech would pull up the porn videos she’d made more than 10 years before, when she was in her early 20s. It did in fact return […]
Joint MHRA/NICE pathway ‘benefits industry over patients’
LSE pharma policy expert contends the MHRA/NICE aligned pathway is weighted towards industry, and calls for an assessment of its impact on the NHS.